Literature DB >> 28468793

Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies.

Ju Ann Tan1,2,3, Natasha Dehghan2, Wenjia Chen4, Hui Xie1,5, John M Esdaile1,2, J Antonio Avina-Zubieta1,2.   

Abstract

OBJECTIVE: To determine the magnitude of all-cause mortality risk in patients with antineutrophil cytoplasmic antibodies-associated vasculitis (AAV) compared with the general population through a meta-analysis of observational studies.
METHODS: We searched Medline and Embase databases from their inception to April 2015. Observational studies that met the following criteria were assessed by two researchers: (1) clearly defined AAV identified by either the American College of Rheumatology 1990 classification criteria or the 2012 Chapel Hill Consensus Conference disease definitions, and (2) reported standardised mortality ratios (SMR) and 95% CI. We calculated weighted-pooled summary estimates of SMRs (meta-SMRs) for all-cause mortality using random-effects model, tested for publication bias and heterogeneity.
RESULTS: Ten studies met the inclusion criteria, comprising 3338 patients with AAV enrolled from 1966 to 2009, and a total of 1091 observed deaths. Overall, we found a 2.7-fold increased risk of death in patients with AAV when compared with the general population (meta-SMR: 2.71 (95% CI 2.26 to 3.24)). Analysis on studies that included only granulomatosis with polyangiitis cases also indicated a similar mortality risk (meta-SMR: 2.63 (95% CI 2.02 to 3.43)). There was no significant publication bias or small-study effect. Subgroup analyses showed that mortality risks were higher in older cohorts, with a trend towards improvement over time (ie, those with their midpoint of enrolment periods that were between 1980-1993 and 1994-1999, vs 2000-2005).
CONCLUSION: Published data indicate there is a 2.7-fold increase in mortality among patients with AAV compared with the general population. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  ANCA; meta-analysis; mortality; observational studies; vasculitis

Mesh:

Year:  2017        PMID: 28468793     DOI: 10.1136/annrheumdis-2016-210942

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  29 in total

Review 1.  Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management.

Authors:  Alvise Berti; Roberto Caporali; Carlomaurizio Montecucco; Giuseppe Paolazzi; Sara Monti
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

2.  All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type.

Authors:  Zachary S Wallace; Xiaoqing Fu; Tyler Harkness; John H Stone; Yuqing Zhang; Hyon Choi
Journal:  Rheumatology (Oxford)       Date:  2020-09-01       Impact factor: 7.580

3.  The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases.

Authors:  April M Jorge; Na Lu; Sarah F Keller; Sharan K Rai; Yuqing Zhang; Hyon K Choi
Journal:  J Rheumatol       Date:  2018-09-01       Impact factor: 4.666

4.  BVAS version 3 and BVAS/GPA: standing on the same line?

Authors:  Sung Soo Ahn; Jang Woo Ha; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2022-07-09       Impact factor: 3.650

5.  Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China.

Authors:  Ronglin Gao; Zhenzhen Wu; Xianghuai Xu; Jincheng Pu; Shengnan Pan; Youwei Zhang; Shuqi Zhuang; Lufei Yang; Yuanyuan Liang; Jiamin Song; Jianping Tang; Xuan Wang
Journal:  Clin Exp Med       Date:  2022-10-16       Impact factor: 5.057

6.  Association of renal transplantation with reduced risk of myocardial infarction and ischemic stroke in ANCA-associated vasculitis: An observational cohort study.

Authors:  Claire Cook; April Jorge; Xiaoqing Fu; John Niles; Anushya Jeyabalan; Reza Zonozi; John H Stone; Yuqing Zhang; Hyon K Choi; Zachary S Wallace
Journal:  Semin Arthritis Rheum       Date:  2021-09-26       Impact factor: 5.532

7.  Topic modeling to characterize the natural history of ANCA-Associated vasculitis from clinical notes: A proof of concept study.

Authors:  Liqin Wang; Eli Miloslavsky; John H Stone; Hyon K Choi; Li Zhou; Zachary S Wallace
Journal:  Semin Arthritis Rheum       Date:  2020-12-24       Impact factor: 5.532

8.  Impact of Cardiovascular Risk Factors on the Occurrence of Cardiovascular Events in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides.

Authors:  Camille Roubille; Soledad Henriquez; Cédric Mercuzot; Claire Duflos; Bertrand Dunogue; Karine Briot; Loic Guillevin; Benjamin Terrier; Pierre Fesler
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

9.  A cohort study to investigate sex-specific differences in ANCA-associated glomerulonephritis outcomes.

Authors:  Jennifer Scott; Carolina Canepa; Antonia Buettner; Louise Ryan; Bróna Moloney; Sarah Cormican; Cathal Walsh; Arthur White; Alan D Salama; Mark A Little
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

10.  Novel mortality-predicting index at diagnosis can effectively predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Hyunsue Do; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  J Clin Lab Anal       Date:  2021-06-28       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.